We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » J&J, House Committee Disagree on FDA OK of ‘Phantom Recall’
J&J, House Committee Disagree on FDA OK of ‘Phantom Recall’
October 4, 2010
Johnson & Johnson (J&J) has failed to provide a House committee with proof that FDA officials agreed to a “soft market withdrawal” of defective Motrin, instead of an official recall, though the company says its emails prove the agency was aware of the action.